stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Revenue growth
Recursion Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 56.2%, up 29.3 percentage points from fiscal 2025 (26.9%). Over the past ten years it has ranged from 0.00% (fiscal 2019) to 291.5% (fiscal 2022); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 26.9% | (5.08) |
| FY2024 | 32.0% | 20.12 |
| FY2023 | 11.9% | (279.58) |
| FY2022 | 291.5% | 0.00 |
| FY2022 | 291.5% | 134.57 |
| FY2021 | 156.9% | 0.00 |
| FY2021 | 156.9% | 86.04 |
| FY2020 | 70.9% | 0.00 |
| FY2020 | 70.9% | 70.85 |
| FY2019 | 0.00% | 0.00 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 258.5% | 318.59 |
| Jun 2026 | −60.1% | (3.99) |
| Mar 2026 | −56.1% | (737.85) |
| Dec 2025 | 681.7% | 761.90 |
| 23 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| RXRX Recursion Pharmaceuticals, Inc. | 56.2% |
| VCEL Vericel Corporation compare | 25.3% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −26.4% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement